EXTRACELLULAR REGULATED KINASE 2 (ERK2)

摘要

The present invention relates to a method of identifying and/or obtaining a compound or a plurality of compounds useful in the prevention or treatment of cardiac diseases which comprises the quantification of the activity of Raf-1, MEK1/2 and/or Erk1/2 depending on said compound. Preferably said compound is an inhibitor or antagonist of the signal cascade which is recruited into the sarcomere and leads to activation of Raf-1, MEK1/2 and/or Erk1/2, since said activation results in translocation of Erk2 into sarcomeres and induction of sarcomeric remodeling. Furthermore, the present invention relates to pharmaceutical compositions for prevention or treatment of hypertrophy, in particular congestive heart failure (CHF) comprising the identified and/or obtained compound or a plurality of compounds as an active ingredient.